<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706936</url>
  </required_header>
  <id_info>
    <org_study_id>IR2020001474</org_study_id>
    <nct_id>NCT04706936</nct_id>
  </id_info>
  <brief_title>Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma</brief_title>
  <official_title>Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carbiogene Therapeutics Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy&#xD;
      (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is&#xD;
      designed based on the fourth-generation of CAR-T techonology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade 3 or 4 treatment related adverse effect</measure>
    <time_frame>24 weeks after last dose of CAR-T treatment</time_frame>
    <description>All the CAR-T treatment related adverse events，including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) after treated by CAR-T treatment</measure>
    <time_frame>up to 2 years after CAR-T treatment</time_frame>
    <description>ORR will be assessed and graded by the international Myeloma Working Group (IMWG) Unified response criteria for multiple myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of CAR-T cells (implantation endpoint)</measure>
    <time_frame>up to 2 years after CAR-T treatment</time_frame>
    <description>To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the &quot;implantation endpoint&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years after CAR-T treatment</time_frame>
    <description>From date of inclusion to date of progression, relapse, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 2 years after CAR-T treatment</time_frame>
    <description>The length of time that a participant's disease did not progress during and after CAR-T treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Anti-BCMA CAR-T (CBG-002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects were intravenous administrated with CBG-002.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-BCMA CAR-T</intervention_name>
    <description>Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.</description>
    <arm_group_label>Anti-BCMA CAR-T (CBG-002)</arm_group_label>
    <other_name>CBG-002 CAR-T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamid</intervention_name>
    <description>300mg/m2/d</description>
    <arm_group_label>Anti-BCMA CAR-T (CBG-002)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2/d</description>
    <arm_group_label>Anti-BCMA CAR-T (CBG-002)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with relapsed/refractory multiple myeloma aged 18-75 years;&#xD;
&#xD;
          2. IHC or bone marrow samples confirmed by flow cytometry-plasma cell membrane is&#xD;
             positive for BCMA expression;&#xD;
&#xD;
          3. Relapsed/refractory patients who meet the following conditions:&#xD;
&#xD;
               1. Ineffective or disease progression after receiving bortezomib (proteasome&#xD;
                  inhibitor) and lenalidomide for 3 courses;&#xD;
&#xD;
               2. Ineffective or disease progression after receiving the original treatment plan&#xD;
                  for 3 courses;&#xD;
&#xD;
               3. The interval between the last treatment and disease progression is more than 30&#xD;
                  days;&#xD;
&#xD;
               4. There is currently no indication for hematopoietic stem cell transplantation, or&#xD;
                  the patient refuses to do hematopoietic stem cell transplantation;&#xD;
&#xD;
               5. The definition of disease progression refers to the &quot;2014 IMWG Standards&quot;, and at&#xD;
                  least meets the following 1 items:&#xD;
&#xD;
             e.1 Serum M protein ≥ 0.5 g/dL;&#xD;
&#xD;
             e.2 Urine M protein ≥ 200 mg/24 h;&#xD;
&#xD;
             e.3 If the serum FLC ratio is abnormal, the patient's FLC level ≥ 10 mg/dL (100 mg/L);&#xD;
&#xD;
             e.4 Evaluable plasmacytoma confirmed by biopsy;&#xD;
&#xD;
             e.5 Increase in the proportion of bone marrow plasma cells ≥25% (absolute increase&#xD;
             ≥10%);&#xD;
&#xD;
             e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells;&#xD;
&#xD;
          4. Estimated survival time&gt; 12 weeks;&#xD;
&#xD;
          5. The disease status can be assessed and meet at least one of the following:&#xD;
&#xD;
               1. Serum M-protein ≥10 g/L;&#xD;
&#xD;
               2. 24h urine M-protein ≥200mg;&#xD;
&#xD;
               3. Serum FLC≥5mg/dL;&#xD;
&#xD;
               4. Plasma cell tumors that can be assessed by testing or images;&#xD;
&#xD;
               5. The proportion of bone marrow plasma cells ≥ 30%;&#xD;
&#xD;
          6. ECOG physical status score 0-1;&#xD;
&#xD;
          7. Have enough venous access for apheresis or venous blood collection, and there are no&#xD;
             other contraindications for blood cell separation;&#xD;
&#xD;
          8. WBC ≥ 1.5×109/L; PLT ≥ 45×109/L;&#xD;
&#xD;
          9. Serum creatinine ≤ 1.5 upper limit of normal (ULN) (excluding patients with myeloma&#xD;
             nephropathy);&#xD;
&#xD;
         10. ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN.&#xD;
&#xD;
        All laboratory test results within the above range should have no ongoing continuous&#xD;
        supportive treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Subjects who meet any of the following criteria cannot be selected for this study:&#xD;
&#xD;
          1. Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine&#xD;
             within 2 weeks before enrollment or single cell collection, or cell therapy within 8&#xD;
             weeks before treatment;&#xD;
&#xD;
          2. HCV or HIV positive; any uncontrollable active infection, including active&#xD;
             tuberculosis, HBV DNA level ≥1×103 copies/mL;&#xD;
&#xD;
          3. Active infections occurred within 72 hours before cleansing; as long as there is no&#xD;
             evidence of active infection and antibiotics are not in the list of prohibited drugs,&#xD;
             subjects who continue to use preventive antibiotics, antifungal drugs or antiviral&#xD;
             drugs are not excluded;&#xD;
&#xD;
          4. The current systemic use of cyclosporine or steroid drugs such as dexamethasone,&#xD;
             recent or current use of inhaled steroids is not excluded;&#xD;
&#xD;
          5. Renal insufficiency, serum creatinine&gt; 1.6mg/dL (excluding patients with myeloma&#xD;
             nephropathy);&#xD;
&#xD;
          6. Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase&#xD;
             (ALT)&gt;2.5 times ULN and direct bilirubin&gt;1.5 times ULN;&#xD;
&#xD;
          7. Hyponatremia, blood sodium &lt;125 mmol/L;&#xD;
&#xD;
          8. Baseline serum potassium &lt;3.5 mmol/L (potassium supplementation can be given before&#xD;
             participating in the study, and serum potassium recovery above this standard is not&#xD;
             excluded);&#xD;
&#xD;
          9. Pregnant or lactating women;&#xD;
&#xD;
         10. Other serious diseases that may restrict subjects from participating in this trial&#xD;
             (such as central nervous system disease, severe heart insufficiency, myocardial&#xD;
             obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6&#xD;
             months , Active autoimmune diseases, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbin Qian</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenbin Qian</last_name>
    <phone>13605801032</phone>
    <email>qianwb@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbing Qian, M.D.,PhD.</last_name>
      <phone>+8613605801032</phone>
      <email>qianwb@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCMA</keyword>
  <keyword>Chimeric antigen receptor T cell</keyword>
  <keyword>Adoptive cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

